Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2013

View Archived Issues

Researchers at Roche present new Mdm2 inhibitors for cancer

Eli Lilly reports topline results from two global phase III ramucirumab studies

Phase I results show promising oncolytic activity for the anti-HB-EGF antibody U3-1565

NovaDigm Therapeutics begins phase Ib/IIa trial of NDV-3 candidiasis vaccine

Researchers from PharmaMar present first-in-human results for PM-060184

CRLX-101 safely combined with Avastin in phase Ib/IIa trial in renal cell carcinoma

Exelixis meets enrollment target in phase III COMET-1 trial

Neuropore Therapies discloses novel agents for neurodegenerative diseases

Nektar reports preliminary topline results from phase II NKTR-181 trial

Korean researchers patent new c-Met inhibitors

4SC Discovery grants Panoptes right to develop novel compound for severe eye diseases

Scientists at FibroGen synthesize novel PHD1 inhibitors

Bayer files for approval of Nexavar for treatment of thyroid cancer in Japan

FDA grants orphan drug designation to Zalicus' Z-160 for management of postherpetic neuralgia

New HIV integrase inhibitors disclosed by Bristol-Myers Squibb

Researchers at Dr. Reddy's Laboratories divulge new KOR agonists

Long-acting GLP-1 analogue shows promise in diabetic mice

EMA accepts olaparib MAA for review

FDA approves new dosing for CSL Behring's immunoglobulin G replacement therapy

Bioheart reports preliminary data from phase I ANGEL trial

FDA grants Titan Pharmaceuticals meeting regarding Probuphine NDA

Durata Therapeutics submits NDA in U.S. for dalbavancin

MAA filing for naloxegol for opioid-induced constipation accepted by EMA

Novartis files application for ruxolitinib in Japan

Axerion Therapeutics' prion protein program selected for NIH support

One-step genetic engineering of conditional transgenic mouse models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...